(Good Medical) – An injection to treat facial wrinkles is expected to rival Allergan's Botox after US regulators approved Evolus Inc.'s cheaper treatment on Friday, boosting its action to around 5 percent after the bell .
PHOTO: A Botox vial and a syringe are seen in Athens, Greece on December 12, 2017. Good Medical / Costas Baltas Good Medical / Mike Segar
Evolus Jeuveau's approval to treat lion wrinkles occurs about eight months after the agency refused to approve the drug, due to deficiencies in the chemistry and manufacture of the product.
"We consider that Evolus' entry into this market is very disruptive," said David Moatazedi, CEO of Evolus, in an interview granted before the FDA decision.
Evolus expects Jeuveau to be sold at 20-25% lower than Botox and is likely to be available throughout the US in physician's offices as of spring 2019, the company said.
Although Botox faces challenges posed by competing treatments for its therapeutic uses, its cosmetic uses have not yet been widely disputed.
Botox was launched in 2002 and, over the years, it has gone from a cosmetic injection to a treatment for migraines and bladder dysfunction, generating $ 3.58 billion sales for Allergan in 2018.
Alternatives to Botox such as anti-wrinkle injections such as Nestle's Dysport or Merz Pharma's Xeomin have not resulted in Botox's success as they need to be taken more frequently.
As it prepared to face the competition, Allergan announced last year its intention to double its spending on direct-to-consumer advertising and increase its Botox sales force.
Revance Therapeutics, headquartered in Newark, Calif., Is also developing a rival against Botox, which may have a longer effect on the treatment of wrinkles.
"The combination of Allergan that doubles the investment in advertising for Botox, the under-penetration of the category of consumers … our entry into Jeuveau will generate considerable interest, not only in the doctor … but also for consumers, "said Moatazedi. I said.
(This version of history removes superfluous words in paragraph 7)
Manas Mishra reportage in Bengaluru; Edited by Sai Sachin Ravikumar and Arun Koyyur